ProKidney Corp.
PROK
NASDAQ·Healthcare·Biotechnology·Mkt cap $675.9M
$2.01
▲ +4.69%
P/E
-6.48
Mkt Cap
$675.9M
52-Wk Range
$1.30–$3.48
52-Week Range
$1.30 - $3.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 6.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+17.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PROK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.15 vs -$0.14 consensus (-7.1% surprise). Revenue of $150.0K vs $186.3K expected (-19.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.1%
Revenue trend · last 2Q
—
-32%
Q1 26
Q2 26
$226.0K
$150.0K
Margins · last 2Q
Gross
0.0%
Operating
0.0%
Profit
-12009.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 18, 2026
vs Industry
How PROK stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.